PDS Biotechnology to present immune response data from VERSATILE-002 trial

PDS Biotechnology announced that an abstract detailing immune response data from the VERSATILE-002 Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA, in patients with unresectable, recurrent or metastatic human papillomavirus 16-positive head and neck cancer has been accepted for presentation at the European Society for Medical Oncology Congress 2023. The abstract, titled, “Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma,” reports on the ability of PDS0101 in combination with KEYTRUDA to induce the right type of HPV16-specific multifunctional T cell responses in the treatment of advanced HPV16-positive head and neck cancer. PDS0101 is designed to stimulate a potent targeted T cell attack against HPV16-positive cancers. The immunological clinical data demonstrates the immunotherapy’s potential to generate clinically-relevant multifunctional HPV16-targeted CD8 and CD4 T cells with minimal toxicity in advanced head and neck cancer patients.